In the claims:

1. (currently amended) A compound of formula (I)

$$R^5$$
 R^4
 R^3
 R^2
 R^6
 R^7
 X
 R^1

X is CH₂ or SO₂

R¹ is an optionally substituted aryl-or heteroaryl ring;

R² is carboxy, cyano, -C(O)CH₂OH, -CONHR⁸, -SO₂NHR⁹, tetrazol-5-yl, <u>or</u> SO₃H, or a group of formula (VI)

(VI)

where R^8 is selected from hydrogen, alkyl, aryl, cyano, hydroxy. - SO_2R^{12} where R^{12} is alkyl, aryl, heteroaryl, or haloalkyl, or R^8 is a group-(CHR¹³)_r-COOH where r is an integer of 1-3 and each R^{13} group is independently selected from hydrogen or alkyl; R^9 is hydrogen, alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally subtituted substituted heteroaryl such as 5 or 6 membered heteroaryl groups, or a group COR¹⁴ where R^{14} is alkyl, aryl, heteroaryl or haloalkyl; R^{10} and R^{14} are independently selected from hydrogen or alkyl, particularly $C_{1,4}$ alkyl;

R³ is hydrogen, a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl,

optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted aralkyloxy, or optionally substituted cycloalkyl;

R⁴ is a group NHCOR¹⁵, or NHSO₂R¹⁵ or OCONR¹⁶R¹⁷ where R¹⁵ is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl-and R¹⁶ and R¹⁷ are independently substituted from hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl, with the proviso that at least one of R¹⁶ or R¹⁷ is other than hydrogen, or R¹⁶ and R¹⁷ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms; and R⁵, R⁶ and R⁷ are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl group groups or optionally substituted heterocyclic groups; and further provided that when R⁴ is a group NHCOR¹⁵, R¹⁵ is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.

- 2. (currently amended) A compound according to claim 1 wherein a group R¹⁵, R⁴⁶ and R⁴⁷ as they appear as it appears in the definition of R⁴, is substituted by at least one functional group, or an aryl or heterocyclyl group groups, either of which may themselves be substituted by one or more functional groups or further aryl or heterocyclyl groups.
- 3. (currently amended) A compound according to any one of the preceding claims claim 1 wherein R⁴ is a group NHCOR¹⁵ or NHSO₂R¹⁵ and R¹⁵ is a substituted alkyl group or an optionally substituted heterocyclyl or optionally substituted phenyl group.
- 4. (currently amended) A compound according to claim 3 wherein R^{15} is alkyl substituted by a group of formula $NR^{19}R^{20}$ where R^{19} and R^{20} are independently selected from hydrogen or optionally substituted hydrocarbyl, or R^{19} and R^{20} together form an optionally substituted ring which optionally contains further heteroatoms such as $S(O)_m$, oxygen and nitrogen, n is an integer of 1 or 2, and m is 1 or 2.
- 5. (currently amended) A compound according to any one of the preceding claims claim 1 where R^2 is carboxy.

- 6. (currently amended) Λ compound according to any one of the preceding claims claim 1 wherein R^1 is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.
- 7. (currently amended) A compound according to any one of the preceding claims claim 1 where X is CH₂.
- 8. (currently amended) A process for preparing a compound according to claim 1 which process comprises either

(a) where R⁴ is NHCOR¹⁵ or NHSO₂R⁴⁵; reacting a compound of formula (VII)

$$R^{5}$$
 R^{6}
 R^{7}
 R^{1}
 (VII)

where X, R^1 , R^3 , R^5 , R^6 and R^7 are as defined in claim 1, and R^2 is a group R^2 as defined in relation to formula (1) or a protected form thereof, with a compound of formula (VIII)

where Z is a leaving group and R^{22} is a group COR^{15} or SO_2R^{15} where R^{15} is group R^{15} as defined in relation to formula (I) or a precursor thereof;

or (b) where R4 is a group OCONR16R17, reacting a compound of formula (VIIA)

(VIIA)

where X, R^{2^2} , R^4 , R^3 , R^5 , R^6 and R^7 are as defined claim 1 and R^2 is a group R^2 as defined in claim 1 or a protected form thereof, with a compound of formula (VIIIA)

Z-CONR⁴⁶R⁴⁷
(VIIIA)

where Z, R 16 and R 17 are as defined above;

and thereafter if desired or necessary:

- (i) converting a precursor group R¹⁵ to a group R¹⁵ and/or converting a group R¹⁵ to a different such group; and
- (ii) deprotecting a group R² to a group R².
- 9. (currently amended) Λ pharmaceutical composition comprising a compound according to any one of claims 1 to 7 claim 1 in combination with a pharmaceutically acceptable carrier.
- 10. (currently amended) A method for antagonizing an MCP-1 (Monocyte Chemoattractant Protein-1) or RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) mediated effect in a warm blooded animal in need of such treatment comprising administering to said animal an effective amount of aA compound according to any one of claims 1 to 7claim 1, a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof, for use in the preparation of a medicament for use in the treatment of disease mediated by monocyte chemoattractant protein 1 or RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted), such as inflammatory disease.
- 11. (new) A method for treating inflammation in a warm blooded animal in need of such treatment comprising administering to said animal an effective amount of a compound according to claim 1, a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.